Featured Research

from universities, journals, and other organizations

Promising results shown for kidney cancer drug

Date:
February 8, 2010
Source:
Sbarro Health Research Organization
Summary:
The drug pazopanib (Votrient) slowed the progression of advanced renal cell carcinoma, a form of kidney cancer, in patients by 54 percent, according to a new study.

The drug pazopanib (Votrient) slowed the progression of advanced renal cell carcinoma (RCC), a form of kidney cancer, in patients by 54% percent, according to a new study published in the Journal of Clinical Oncology.

"Advanced renal cell carcinoma remains a challenging disease, but the outlook for patients has improved in the past year -- including the addition of pazopanib, which targets multiple pathways within cancer cells," study author Dr. Cora N. Sternberg, chief of the medical oncology department at the San Camillo and Forlanini Hospital in Rome, Italy, said in a news release from the American Society of Clinical Oncology.

Dr. Sternberg also serves as the director of the scientific advisory board for the Columbus Cancer Foundation, a international nonprofit organization devoted to supporting basic cancer research.

Pazopanib inhibits the development of blood vessels that tumors need to grow and spread.

"These clinical findings are indeed very encouraging," said Dr. Antonio Giordano, M.D., Ph.D., the founder and director of the Sbarro Health Research Organization located at Temple University in Philadelphia, PA. "We will look forward to the further studies which are currently evaluating the impact of pazopanib on the overall survival of treated patients."

In a phase 3 study, 233 patients with previously untreated locally advanced or metastastic kidney cancer and 202 other patients with kidney cancer who had been previously treated with interleukin or interferon, were randomly assigned to receive the oral drug pazopanib or a placebo.

Results showed that the time it took for a patient's disease to progress was more than double for the group receiving pazopanib (9.2 months), compared with the placebo group (4.2 months). The most dramatic effect was seen in previously untreated patients (11.1 months for the pazopanib group vs. 2.8 for the placebo) and persisted among those previously treated (7.4 vs. 4.2 months, respectively). The study is ongoing to determine how the drug impacts overall survival.

Common side effects of pazopanib included diarrhea (52 percent), hypertension (40 percent), hair color changes (38 percent), nausea (26 percent), weight loss (22 percent) and vomiting (21 percent).


Story Source:

The above story is based on materials provided by Sbarro Health Research Organization. Note: Materials may be edited for content and length.


Cite This Page:

Sbarro Health Research Organization. "Promising results shown for kidney cancer drug." ScienceDaily. ScienceDaily, 8 February 2010. <www.sciencedaily.com/releases/2010/02/100204101723.htm>.
Sbarro Health Research Organization. (2010, February 8). Promising results shown for kidney cancer drug. ScienceDaily. Retrieved September 1, 2014 from www.sciencedaily.com/releases/2010/02/100204101723.htm
Sbarro Health Research Organization. "Promising results shown for kidney cancer drug." ScienceDaily. www.sciencedaily.com/releases/2010/02/100204101723.htm (accessed September 1, 2014).

Share This




More Health & Medicine News

Monday, September 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
New Drug Could Reduce Cardiovascular Deaths

New Drug Could Reduce Cardiovascular Deaths

Newsy (Aug. 30, 2014) The new drug from Novartis could reduce cardiovascular deaths by 20 percent compared to other similar drugs. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins